Meridian wins FDA clearance for new campylobacter test

Source of Article:


Thu. February 05, 2009; Posted: 09:35 AM

Feb 05, 2009 (Datamonitor via COMTEX) -- -- Meridian Bioscience, a fully integrated life science company, has received the FDA clearance for a new test for Campylobacter. Launched as Premier Campy, the rapid enzyme immunoassay test provides for optimized detection of Campylobacter infection, the company said.

According to the company, there is a significant need for the Premier Campy test because it provides a solution to several concerns associated with culture testing, currently the most commonly practiced lab technique for detecting the campylobacter bacteria.

Premier Campy dramatically reduces these concerns with a consistent enzyme immunoassay method that measures the antigen instead of the fragile bacteria in an environment that is less inhibitory than current culturing procedures, the company claimed.

John Kraeutler, CEO of Meridian, said: "This new assay solidifies our position as a leader in rapid, accurate testing methods in food borne testing. Premier Campy is already in distribution via Meridian Bioscience Europe for the company's European markets and was also recently approved for sale in Canada."

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

For full details on Meridian Bioscience Inc (VIVO) click here. Meridian Bioscience Inc (VIVO) has Short Term PowerRatings of 2. Details on Meridian Bioscience Inc (VIVO) Short Term PowerRatings is available at This Link.



Main Page

setstats            Copyright (C) All rights reserved under

            If you have any comments, please  send your email to